SpaceX astronauts splashdown safely off Southern California coast
According to SpaceX, the Dragon spacecraft undocked from the ISS at 6 05 p.m. EDT on Friday, Aug. 8, and completed a series of precise 'orbit-lowering maneuvers' before re-entering Earth's atmosphere.
The capsule made a successful splashdown at 11:33 a.m. EDT on Saturday in the Pacific Ocean, approximately 17 hours since the crew's departure.
Four astronauts safely returned to Earth Saturday morning with a splashdown off the coast of San Diego. (Credit: SpaceX)
Aboard the spacecraft were NASA astronauts Anne McClain and Nichole Ayers, Japan Aerospace Exploration Agency astronaut Takuya Onishi, and Roscosmos cosmonaut Kirill Peskov. All four crewmembers are reported to be in good health following recovery operations.
The mission, launched from Kennedy Space Center in Florida on March 14, marked a 145-day stay in orbit. The Dragon capsule autonomously docked with the ISS just over a day after launch and supported a wide range of scientific research during its time in space.
Four astronauts safely returned to Earth Saturday morning with a splashdown off the coast of San Diego. (Credit: SpaceX)
While in orbit, Crew-10 contributed to experiments aimed at advancing future human space exploration and improving life on Earth, including studies on microgravity's effects on human health and new technologies for long-duration missions, SpaceX officials explained.
This Dragon spacecraft has now completed multiple missions, having previously flown NASA's Crew-3, Crew-5, and Crew-7 missions. The Falcon 9 rocket used in this mission also marked its second flight, previously launching the SES 03b mPOWER satellite.
NASA and SpaceX streamed the re-entry and splashdown live via webcast and on the new X TV app, giving space enthusiasts a front-row seat to the exciting conclusion of the mission.
The safe return off California's southern coast marks another milestone in the ongoing partnership between NASA and SpaceX as they continue to advance crewed spaceflight capabilities.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
14 minutes ago
- Medscape
Brain Stimulation Promising for Progressive Aphasia
Transcranial magnetic stimulation (TMS) may augment standard language therapy to help slow the progression of primary progressive aphasia (PPA), a neurodegenerative disorder that erodes communication. In a randomized sham-controlled clinical trial, 6 months of active intermittent theta-burst TMS plus language therapy improved or mitigated decline in regional brain metabolism, trained language abilities, functional impairment, and neuropsychiatric symptoms in adults with PPA. The study was published online on August 11 in JAMA Network Open . Added Value? PPA is a heterogeneous clinical syndrome marked by progressive speech and/or language impairment. Most cases stem from frontotemporal degeneration or Alzheimer's disease. There are currently no effective drug treatments, although speech-language therapy has proven to be helpful. TMS can induce changes in cortical excitability, potentially promoting the reorganization of language networks, and has shown promise as adjunctive treatment for post-stroke aphasia. Previous studies examining the short-term effects of TMS on PPA reported 'encouraging' results, but the longer-term effects, beyond more than a few weeks of intervention, have not been examined, until now. For the study, the researchers led by Jordi Matias-Guiu, MD, PhD, with the Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain, recruited 63 adults with early-stage PPA (42 women; mean age, 72 years). Participants were randomized (2:1) to either active intermittent theta-burst TMS or sham TMS for 6 months, immediately followed by evidence-based language therapy for PPA. The trial consisted of a 24-week treatment that included a 2-week intensive course, in which active TMS or sham TMS combined with language therapy was applied daily, followed by a maintenance phase in which the same stimulation was applied weekly for 22 weeks. Participants were assessed at baseline, 3 months after the start of the treatment, and at the end of the treatment (6 months following baseline). The main outcome was the standardized uptake value ratio (SUVR) on FDG PET imaging in the left hemisphere, assessed at baseline and at 6 months (immediately following the intervention). Feasible, Effective Option The primary outcome was positive with higher adjusted mean SUVR in the active group than in the sham TMS group (0.78 vs 0.77; P = .046). Active TMS was also associated with significant improvement on all secondary language outcomes at 6 months, including the mini linguistic state examination, with an adjusted mean difference at 6 months of 7.71 ( P = .002). Patients in the sham group worsened on this measure compared with those in the active group. Active TMS also led to improvement in confrontation naming of trained words, which improved by a mean 23.8 points in active recipients compared with sham TMS recipients. Functional independence also benefited, with daily-living scores falling (indicating better performance) by 5.4 points in the active group compared with the sham TMS group. Neuropsychiatric symptoms eased as well, with a 4-point advantage on the neuropsychiatric inventory scale. There were no significant differences in the number of adverse events. Adherence to treatment protocol was high (92%). 'Overall, these findings suggest that the combination of TMS and language therapy is a feasible and effective treatment option for PPA,' the researchers concluded. They said future studies should investigate the potential for TMS paired with an evidence-based speech-language intervention to sustain or extend these benefits beyond 6 months.
Medscape
44 minutes ago
- Medscape
Race, Ethnicity Influences Depression Risk in Vitiligo
TOPLINE: In a study, Black and Hispanic patients with vitiligo were at a significantly greater risk for depression than control individuals, which was not the case for White and Asian patients with vitiligo. METHODOLOGY: Researchers conducted a retrospective cross-sectional study of 1087 patients with vitiligo using electronic health records from the National Institutes of Health All of Us Program between 2018 and 2024. They were compared with 5435 individuals without vitiligo, matched by age, sex, race/ethnicity, education, income, and insurance status. In both groups, the mean age was 63.2 years; about 63% were women; 49% were White, 19% were Black, 3% were Asian, and 24% were Hispanic patients. The primary outcome was risk for depression after adjusting for comorbidities such as autoimmune and thyroid diseases, Hashimoto thyroiditis, and diabetes. TAKEAWAY: Overall, patients with vitiligo showed an increased risk for depression (adjusted odds ratio [aOR], 1.34; 95% CI, 1.16-1.54) compared with those without vitiligo. Black patients with vitiligo had more than a twofold higher risk for depression (aOR, 2.13; 95% CI, 1.55-2.91) than Black patients without vitiligo. Hispanic patients also had a significantly higher risk for depression (aOR, 1.45; 95% CI, 1.09-1.94), and non-Hispanic patients were also at a higher risk for depression (aOR, 1.29; 95% CI, 1.09-1.52) than Hispanic and non-Hispanic control individuals without vitiligo, respectively. The risk for depression in White individuals (aOR, 1.06; 95% CI, 0.85-1.29) and in Asian individuals with vitiligo (aOR, 0.70; 95% CI, 0.15-2.38) was not significantly increased when compared with White and Asian patients without vitiligo, respectively. IN PRACTICE: 'These findings underscore significant variation in the mental health burden of vitiligo across racial and ethnic groups,' the study authors wrote. 'Black and Hispanic patients with vitiligo,' they added, 'experience significantly elevated depression risk, potentially reflecting greater lesion visibility, cultural stigma, and differences in access to mental health and dermatologic services.' SOURCE: The study was led by Matthew J. Yan, BS, BA, Division of Dermatology, Department of Medicine at the University of California, Los Angeles, and was published online on August 5 in JAAD International. LIMITATIONS: The study did not assess vitiligo lesion visibility, treatment details, or age of onset. Sample sizes for Asian patients were small and could limit generalizability. DISCLOSURES: The study did not receive any funding. One author disclosed receiving research support, advisory, and speaker fees from AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO, UCB, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Regeneron, and Pfizer. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Bloomberg
an hour ago
- Bloomberg
Europe's Ariane 6 Rocket Slated to Launch in SpaceX Challenge
A troubled European rocket critical to the continent's goal of reducing its reliance on Elon Musk's SpaceX is set to thunder off a launchpad for only its third-ever mission. The Ariane 6, which had its debut in July 2024 and is the centerpiece of Europe's space ambitions, will be sending an Airbus SE -made satellite into a polar orbit for weather forecasting and climate monitoring. The launch in French Guiana is scheduled at 8:37 p.m. New York time on Tuesday.
